If you're selling biotech services or solutions, you already know the problem - your prospects are drowning in generic pitches and they're skeptical of anyone they don't know. A lab director at a biotech firm gets maybe 40+ cold emails a week. Most are noise. Your email needs to cut through that noise with specificity, credibility, and a clear reason they should care.
Cold email in biotech is different from selling SaaS or consulting. Your buyers are technical. They care about data, regulatory compliance, and proven outcomes - not hype. And they're selective about who gets time on their calendar. The good news: if you understand these differences and build your approach around them, you'll have almost no competition because most people sending cold emails to biotech don't.
Know Your Target Decision-Maker (and Why It Matters)
In biotech, the person you're reaching out to depends entirely on what you're selling. If you're selling lab equipment, you're talking to procurement or a lab manager. If you're selling regulatory consulting, you're talking to a compliance officer or quality assurance director. If you're selling data analysis software, you might be talking to a research director or bioinformatics lead.
The mistake most people make is lumping all "biotech" together. You need to be specific about title and function. A research director at a 50-person biotech firm is completely different from a research director at a 500-person organization. One has budget authority; the other reports up through layers.
When you're building your lead list, spend time mapping out the actual organizational structure of your target companies. Where does your solution sit in their budget? Who has to sign off? Who is frustrated with the current solution? That's your person.
The Biotech Cold Email Structure That Works
Biotech buyers respond to specificity and data. They don't respond to generic relationship-building emails. Your email needs to be short, credible, and specific to their world.
Here's the structure that gets replies:
Subject line: Reference something specific about their company or a problem in their space. No "quick question" or generic urgency plays.
Quick thought on [Company Name]'s CMC strategy for your Phase 2 timeline
Opening: Lead with a specific, credible observation. Not about them as a person - about their business or their space.
Hey [Name], I noticed [Company Name] filed an IND for [specific program] last quarter. A lot of teams moving into Phase 2 right now are hitting delays on CMC manufacturing - averaging 4-6 months behind timeline.
The bridge: One sentence connecting their situation to why you're writing.
We've worked with 7 biotech firms in your stage on this specific bottleneck.
The ask: Super small. Not a sales call, not "let's chat." A specific question or micro-commitment.
Worth a 15-min call to talk through how others have solved this without derailing timelines?
That's it. Short, specific, credible. Total length: 4-5 lines.
Getting the Specific Intelligence Right
The opening line is where biotech cold email either works or doesn't. You need to know something specific about them - not from their website, but from their actual business activity.
Use these sources:
- SEC filings and investor updates - Biotech companies file IND applications, IPO documents, quarterly updates. These are public. They tell you their current programs, timelines, and strategic priorities.
- Industry publications - STAT News, Endpoints News, FierceBiotech. These cover biotech developments weeks before companies mention them in their own materials.
- LinkedIn activity - Not just connection requests. Look at who they're hiring, what positions are open, who just joined from where. Hiring for a CMC role? They're scaling manufacturing.
- ClinicalTrials.gov - If they're running trials, it's public. You can see phase, enrollment status, timeline.
- Patent filings - Google Patents is free. Recent filings tell you what they're working on next.
This takes time upfront, but it's what separates cold emails that get ignored from ones that get opened and replied to. You're not personalizing with "I saw you went to Stanford" - you're demonstrating that you understand their business.
Subject Lines That Work in Biotech
Biotech decision-makers don't respond to clickbait. They respond to subject lines that signal relevance to their specific situation.
Good subject lines reference their program, their stage, or a specific problem in their space:
Phase 2 CMC timeline - what [Company Name] is doing differently
Or they reference a recent company announcement:
Re: Your Series B announcement - CMC planning question
Or they lead with a number tied to their world:
4-6 months: the CMC delay most biotech teams aren't planning for
Avoid anything cute or vague. No emojis. No "quick question." No subject lines about the reader personally. These people get 50+ emails a day - your subject line needs to be immediately clear why they should care.
The Multi-Touch Sequence
One email doesn't work. In biotech, where decision-cycles are long and people are busy, you need a multi-touch sequence that respects their time and adds value with each touch.
Here's the cadence that works:
- Email 1 (Day 1): The opener. Specific observation, credible, small ask.
- Email 2 (Day 4): Not a follow-up. A value add. Share a relevant article, a case study, or data point specific to their situation. "Thought of you when I saw this report on [specific biotech challenge]."
- Email 3 (Day 8): Short and direct. "Getting back to my earlier note - would this be worth exploring?" One sentence. One link to your calendar.
- Email 4 (Day 12): Shift channels if you can. If they're active on LinkedIn, send them a message there. Different subject line, same value prop, different medium.
- Email 5 (Day 16): Final touch. Assume they're not interested, but leave the door open. "Guessing this isn't a priority right now - but if that changes, here's how to reach me."
Stop after 5 touches. If they haven't replied and they're not active on LinkedIn showing interest, they're not a fit.
The Credibility Question
Biotech buyers need to know you understand their world. Credibility is built in the email body, not on your website.
Use specific examples and data:
- "We've helped 12 biotech firms in Phase 2 accelerate CMC timelines by 3-4 months."
- "Most teams we work with were losing 6+ weeks to [specific problem]."
- "We worked with [similar-stage company] on the same regulatory pathway."
Don't claim expertise you don't have. Biotech people will catch it immediately. If you're new to biotech, be honest and lead with what you do know - the specific problem you solve and how.
Make sure your emails are actually landing in inboxes - bad deliverability undermines all of this work.
Metrics That Matter
In biotech cold email, you're looking at different benchmarks than general B2B:
- Open rate: 25-35% is solid. Biotech audiences are smaller and more skeptical, so open rates tend to be lower than broad B2B, but replies matter more than opens.
- Reply rate: 3-8% is good. You're not looking for volume; you're looking for qualified conversations.
- Meeting rate: 30-50% of replies should turn into meetings. If it's lower, your ask or your follow-up is too aggressive.
- Sales cycle: Expect 60-90 days minimum from first email to signed deal. Biotech doesn't move fast.
Track these. If your open rate is under 20%, your subject lines need work. If your reply rate is under 2%, your email body is generic.
When to Bring in Help
Cold email in biotech is learnable, but it requires deep understanding of your specific segment, the right list infrastructure, and consistent execution. Most people either build this slowly over months or never nail it because they're trying to do it piecemeal alongside other work.
If you're serious about scaling this beyond a handful of outreach attempts, you need systems for list building (finding the right people with the right job titles at the right companies), infrastructure setup (making sure emails actually land), copy that actually reflects biotech realities, and consistent follow-up - the gap between knowing how to do this and actually having it running at scale is substantial. That's where a cold email agency focused on B2B comes in - you handle list sourcing, email setup, writing, and reply management while you focus on closing deals.